Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001874379 | SCV002136050 | uncertain significance | not provided | 2022-09-15 | criteria provided, single submitter | clinical testing | This sequence change replaces arginine, which is basic and polar, with glutamine, which is neutral and polar, at codon 220 of the MGME1 protein (p.Arg220Gln). This variant is present in population databases (rs201465869, gnomAD 0.1%). This variant has not been reported in the literature in individuals affected with MGME1-related conditions. ClinVar contains an entry for this variant (Variation ID: 1368309). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt MGME1 protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV002550419 | SCV003539758 | uncertain significance | Inborn genetic diseases | 2022-10-04 | criteria provided, single submitter | clinical testing | The c.659G>A (p.R220Q) alteration is located in exon 3 (coding exon 2) of the MGME1 gene. This alteration results from a G to A substitution at nucleotide position 659, causing the arginine (R) at amino acid position 220 to be replaced by a glutamine (Q). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Baylor Genetics | RCV003147690 | SCV003836356 | uncertain significance | Mitochondrial DNA depletion syndrome 11 | 2022-03-23 | criteria provided, single submitter | clinical testing | |
Gene |
RCV001874379 | SCV005332515 | uncertain significance | not provided | 2024-03-01 | criteria provided, single submitter | clinical testing | In silico analysis supports that this missense variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |